Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06330064 · ClinicalTrials.gov registry record · Phase 2
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
A Phase 2 study of Recurrent or Metastatic Solid Tumors, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT06330064 is a Phase 2 study of Recurrent or Metastatic Solid Tumors that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 520 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT06330064, a Phase 2 study of Recurrent or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma.
Conditions Studied
Interventions
- DRUG Ifinatamab deruxtecan
Study Locations (20)
California
- Los Angeles Cancer Network - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- Pih Health Hematology Medical Oncology - Whittier
New York
- NYU Langone Health - New York
- Icahn School of Medicine At Mount Sinai Prime - New York
- Clinical Research Alliance - Westbury
Tennessee
- Tn Gynecologic Oncology Group, Llc - Chattanooga
- The West Clinic - Germantown
- SCRI Oncology Partners - Nashville
Texas
- Texas Oncology - West Texas - Amarillo
- Texas Oncology, P.A. - Dallas
- Texas Oncology Gulf Coast - Pearland
Other
- DIABAID - Buenos Aires
- Hospital Aleman - Buenos Aires
- Hospital Sirio Libanes - Caba
Illinois
- Orchard Healthcare Research Inc. - Skokie
Minnesota
- M Health Fairview University of Minnesota Medical Center - Minneapolis
Utah
- University of Utah Hospitals & Clinics - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2028-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06330064
The ClinicalTrials.gov registry entry for NCT06330064 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Ifinatamab deruxtecan is the first listed.
NCT06330064 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06330064 about?
NCT06330064 is a clinical study titled "A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)". This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarci...
What is the current status of trial NCT06330064?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 520 participants. The study started on 2024-04-10. Estimated completion is 2028-07-25.
What conditions does trial NCT06330064 study?
This clinical trial studies the following conditions: Recurrent or Metastatic Solid Tumors.
What interventions are being tested in trial NCT06330064?
The interventions under investigation include: Ifinatamab deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06330064?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06330064 being conducted?
This trial has 20 study locations across California, Illinois, Minnesota, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.